Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.61 |
| ▸ | DNPH1 | O43598 | 3/20 | 0.57 |
| ▸ | FBP1 | P09467 | 2/20 | 0.57 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.57 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.57 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.57 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20266268 | 1.00 | IMPDH2 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL28340155 | 1.00 | IMPDH2 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL2217345 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL22986473 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL27862445 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL12727828 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL4356337 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL188741 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| SCHEMBL188739 | 0.99 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 | |
| Phosphoric Acid SCHEMBL30728570 | 0.98 | IMPDH2 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2026-01-27 | — | — | US | disclosed |
| CN-113784706-B | Multi-layered pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and B vitamins, their preparation and use | 菲尔若国际公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220160744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2022-05-26 | — | — | US | disclosed |
| EP-3965744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | Ferrer Internacional, S.A. (ES) | 2022-03-16 | — | — | EP | disclosed |
| CN-113784706-A | Multi-layered pharmaceutical or nutraceutical solid dosage form comprising pyrimidine and/or purine derivatives and B vitamins, preparation and use thereof | 菲尔若国际公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020224795-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | P2RY10, TYMP, P2RY12 | IMPDH2 799/4885IMPDH1 458/4885TAS1R3 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.